Allogene Therapeutics, Inc. (NASDAQ:ALLO) Expected to Post Q1 2026 Earnings of ($0.43) Per Share

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Equities researchers at Zacks Research raised their Q1 2026 earnings per share (EPS) estimates for shares of Allogene Therapeutics in a research report issued on Wednesday, September 18th. Zacks Research analyst R. Department now expects that the company will post earnings of ($0.43) per share for the quarter, up from their prior forecast of ($0.45). The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.38) per share. Zacks Research also issued estimates for Allogene Therapeutics’ Q2 2026 earnings at ($0.44) EPS and FY2026 earnings at ($1.80) EPS.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. Allogene Therapeutics had a negative net margin of 223,139.98% and a negative return on equity of 50.24%.

Other research analysts have also recently issued research reports about the stock. Citigroup raised their target price on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Piper Sandler began coverage on shares of Allogene Therapeutics in a research note on Friday, May 31st. They set an “overweight” rating and a $11.00 price objective for the company. Truist Financial reissued a “buy” rating and issued a $14.00 target price (down from $17.00) on shares of Allogene Therapeutics in a research note on Friday, August 9th. Oppenheimer initiated coverage on Allogene Therapeutics in a research report on Thursday, August 8th. They set an “outperform” rating and a $11.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Allogene Therapeutics in a research report on Thursday, August 15th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.96.

Allogene Therapeutics Price Performance

ALLO opened at $2.67 on Monday. The stock’s 50 day simple moving average is $2.69 and its 200 day simple moving average is $2.97. The firm has a market cap of $558.03 million, a price-to-earnings ratio of -1.49 and a beta of 0.83. Allogene Therapeutics has a 1 year low of $2.01 and a 1 year high of $5.78.

Hedge Funds Weigh In On Allogene Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. grew its position in shares of Allogene Therapeutics by 23.1% in the 4th quarter. Victory Capital Management Inc. now owns 14,283 shares of the company’s stock worth $46,000 after buying an additional 2,680 shares during the period. Bourgeon Capital Management LLC increased its stake in shares of Allogene Therapeutics by 12.8% during the first quarter. Bourgeon Capital Management LLC now owns 57,200 shares of the company’s stock valued at $256,000 after purchasing an additional 6,500 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Allogene Therapeutics by 85.1% during the first quarter. CANADA LIFE ASSURANCE Co now owns 17,750 shares of the company’s stock valued at $79,000 after purchasing an additional 8,162 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Allogene Therapeutics by 429.6% in the 2nd quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company’s stock worth $25,000 after purchasing an additional 8,734 shares in the last quarter. Finally, Arizona State Retirement System grew its stake in shares of Allogene Therapeutics by 36.1% in the 2nd quarter. Arizona State Retirement System now owns 40,915 shares of the company’s stock worth $95,000 after buying an additional 10,855 shares during the last quarter. Institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).